Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Trauma Surg Acute Care Open ; 2(1): e000101, 2017.
Article in English | MEDLINE | ID: mdl-29766099

ABSTRACT

BACKGROUND: CT scans are heavily relied on for assessment of solid organ injuries complementing clinical examination. These CT scans could also reveal pathologies not related to trauma called incidental findings. We aimed to evaluate the frequency of these findings and their outcome on hospital services. METHODS: A retrospective chart review of prospectively collected data of the emergency department's trauma database from January 2005 to December 2011 to evaluate incidental findings on CT scans on trauma admissions. These incidental findings were divided into three classes: class 1-minor degenerative, non-degenerative, normal variants or congenital finding that does not require further investigation or workup; class 2-findings not requiring urgent intervention with scheduled outpatient follow-up and class 3-all findings that require urgent evaluation/further investigation during the same hospital admission. One-year follow-up was done to review hospital length of stay, trauma clinic follow-up and post-trauma surgery. RESULTS: Of 1000 charts reviewed, 957 were selected after 43 patients were excluded due to incomplete documentation. Of the 957 patients, 385 (40%) were found to have incidental findings. A total of 560 incidental findings were found on the CT scan reports with one-third of patients having multiple findings (144 patients, 37.4%). The largest number of incidental findings were in class 2. The incidental group had significantly longer length of stay after adjusted multivariate analysis (8.7±0.48 vs 6.7±0.55, p=0.005). CONCLUSION: The incidental findings are commonly found during CT imaging in trauma centers and our rate was 40%. Appropriate documentation, communication and follow-up of those findings is necessary. A classification system for these findings practiced nationwide will aid in categorizing the urgency of continued follow-up. This also will help decrease the length of hospital stay and healthcare cost. LEVEL OF EVIDENCE: Level 4.

3.
Ann Surg Oncol ; 23(Suppl 5): 9001-9009, 2016 12.
Article | MEDLINE | ID: mdl-16715435

ABSTRACT

BACKGROUND: Sentinel lymph node biopsy (SLNB) for primary cutaneous head and neck melanoma (CHNM) has been shown to be successful and is the current standard of care for intermediate-thickness melanoma. We evaluated our experience with CHNM associated with SLNB mapping to the region of the parotid gland. METHODS: Retrospective review of a prospectively collected melanoma database identified 1014 CHNMs. Two-hundred twenty-three patients underwent SLNB, and 72 (32%) had mapping in the region of the parotid gland between May 1995 and June 2003. RESULTS: The mean number of SLNs per patient was 2.5. A sentinel lymph node (SLN) was successfully identified in 94% of patients, and in 12%, the SLN was positive for metastatic disease. Biopsy of intraparotid SLNs was performed in 51.4% and of periparotid SLNs in 26.4%, and a superficial parotidectomy was performed in 22.2%. Ten patients were found to have lymph nodes in the parotid region with metastatic disease (eight identified by SLNB), and two (20%) patients developed intraparotid lymph node recurrence in the setting of a negative SLNB. Same-basin recurrence in SLN-negative patients was 3.3% with a median follow-up of 26 months. Facial nerve dysfunction was identified in seven (10%) patients. Facial nerve function returned to preoperative status in all patients. CONCLUSIONS: SLNB for patients with primary CHNM mapping to the parotid gland can be performed with a high degree of accuracy and a low morbidity consisting of temporary facial nerve paresis.


Subject(s)
Ear Neoplasms/pathology , Facial Neoplasms/pathology , Lymph Node Excision , Melanoma/secondary , Neoplasm Recurrence, Local/pathology , Parotid Neoplasms/secondary , Sentinel Lymph Node Biopsy , Sentinel Lymph Node/pathology , Skin Neoplasms/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Cheek , Coloring Agents , Facial Nerve/physiopathology , Facial Nerve Injuries/etiology , Female , Forehead , Humans , Lymph Node Excision/adverse effects , Lymphatic Metastasis , Lymphoscintigraphy , Male , Middle Aged , Parotid Neoplasms/surgery , Parotid Region , Recovery of Function , Retrospective Studies , Sentinel Lymph Node/diagnostic imaging , Sentinel Lymph Node/surgery , Sentinel Lymph Node Biopsy/adverse effects , Tumor Burden , Young Adult
4.
Case Rep Surg ; 2015: 482342, 2015.
Article in English | MEDLINE | ID: mdl-26185704

ABSTRACT

We report a case of a 70-year-old man, with a status after aortic valve replacement, who presented with melena and hypotension. On physical examination, he was hypotensive, but he responded to resuscitation. Esophagogastroduodenoscopy revealed a submucosal mass in the gastric fundus. Imaging of the chest, abdomen, and pelvis showed no evidence of local or distant metastasis. He underwent a partial diaphragmatic resection, gastrectomy, lymphadenectomy, and Roux-en-Y esophagojejunostomy. Pathology showed a gastric squamous cell carcinoma (SCC) invading the diaphragm, with negative margins of resection, and one positive perigastric lymph node. He received chemoradiation, but the patient expired 27 months after surgery.

5.
Case Rep Surg ; 2014: 629672, 2014.
Article in English | MEDLINE | ID: mdl-24991446

ABSTRACT

We report the case of a 40-year-old woman who presented with a large perineal mass with no rectal or vaginal involvement. Imaging could not rule out malignancy. She underwent wide surgical excision. Histological analysis revealed a large atypical leiomyoma, measuring 24 × 12 × 8 cm. Followup after two years showed no recurrence and she has been asymptomatic since surgery. This is the largest perineal leiomyoma reported so far.

6.
Am J Surg ; 206(5): 764-70, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23866764

ABSTRACT

BACKGROUND: Prior studies have demonstrated the prognostic value of pretreatment serum albumin in different types of cancer. The aim of this study was to assess the predictive value of the albumin to globulin ratio (AGR) on survival in breast cancer patients. METHODS: This retrospective study used an unselected cohort of 354 breast cancer patients who had documented total protein and albumin levels prior to chemotherapy. Survival status was obtained from our cancer registry. Survival analysis, stratified by AGR tertiles, was used to evaluate the prognostic value of AGR. RESULTS: Patients in the highest AGR tertiles (AGR > 1.45) had a lower 5-year mortality rate compared with those in the middle (AGR 1.21 to 1.45) and the lowest (AGR < 1.21) tertiles (6% vs. 18% and 32%, P < .001). After adjusting for confounding variables, AGR remained a significant predictor of mortality (P < .002). Moreover, after excluding the patients with albumin levels less than 3.6, the AGR remained a significant predictor of survival (P .0018). CONCLUSIONS: Pretreatment AGR is an independent, significant predictor of long-term mortality in breast cancer patients, even in patients with normal albumin levels.


Subject(s)
Breast Neoplasms/blood , Breast Neoplasms/mortality , Serum Albumin/analysis , Serum Globulins/analysis , Aged , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/blood , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/mortality , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/blood , Carcinoma, Lobular/drug therapy , Carcinoma, Lobular/mortality , Carcinoma, Lobular/pathology , Cohort Studies , Female , Humans , Kaplan-Meier Estimate , Middle Aged , Proportional Hazards Models , Retrospective Studies
7.
J Am Coll Surg ; 201(1): 57-65, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15978444

ABSTRACT

BACKGROUND: Hepatic arterial infusion pump chemotherapy is an important component in the treatment of patients with hepatic metastases. Successful use of a hepatic arterial infusion pump requires a low technical complication rate. We evaluated the complications and longterm durability of these devices at our institution. STUDY DESIGN: Between April 1986 and March 2001, 544 patients underwent hepatic arterial infusion pump placement for treatment of unresectable colorectal liver metastases. Patient- and pump-related data were collected by chart review. Pump-related complications, duration of pump function, and overall patient survival were recorded. RESULTS: Median patient survival was 24 months after pump placement. The incidences of pump failure were 9% at 1 year and 16% at 2 years. Pump complications occurred in 120 (22%) of the patients. Complications that occurred early after operation (< 30 days) were more likely to be salvaged than those occurring late (70% versus 30%, p < 0.001). Increased pump complication rates occurred in the setting of variant arterial anatomy (28% versus 19%, p = 0.02), when the catheter was inserted into a vessel other than the gastroduodenal artery (42% versus 21%, p = 0.004), if the pump was placed during the first half of the study period (1986 to 1993, 25% versus 1994 to 2001, 18%; p = 0.05), and if the surgeon had performed fewer than 25 earlier procedures (< 25, 31% versus > or = 25, 19%; p < 0.002). CONCLUSIONS: In this large single institution experience, pump-related complications were low, the majority of early pump complications were salvaged, and pump complication rates improved as institutional experience accumulated. Longterm durability of pump function was excellent.


Subject(s)
Hepatic Artery , Infusion Pumps, Implantable , Liver Neoplasms/secondary , Catheterization/instrumentation , Colectomy , Colorectal Neoplasms/pathology , Equipment Design , Equipment Failure , Female , Follow-Up Studies , Hepatic Artery/pathology , Humans , Infusion Pumps, Implantable/adverse effects , Length of Stay , Liver Neoplasms/drug therapy , Longitudinal Studies , Male , Middle Aged , Retrospective Studies , Survival Rate , Thrombosis/etiology , Time Factors
8.
Int J Colorectal Dis ; 18(6): 487-92, 2003 Nov.
Article in English | MEDLINE | ID: mdl-12783251

ABSTRACT

BACKGROUND AND AIMS: Although the standard of care for T3 and/or N1-2 rectal cancers includes adjuvant chemoradiation, it is unclear whether T3 N0 patients with limited microscopic perirectal fat invasion warrant further therapy. Our aim was to determine the prognostic significance of gross perirectal fat invasion, or depth of microscopic perirectal fat invasion, in T3 N0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. PATIENTS AND METHODS: Utilizing a prospective database, the medical records of 108 patients who underwent a potentially curative resection for T3 N0 rectal cancer between June 1986 and December 1994 were analyzed. All pathological specimens were re-reviewed by a single pathologist, and extent of perirectal fat invasion was measured in millimeters. Patients who received either preoperative or postoperative adjuvant therapy were excluded. RESULTS: Macroscopic perirectal fat invasion (T3 gross) was present in 49 cases, absent in 40 cases (T3 microscopic), and not reported in 19 cases. Rectal cancers were stratified by extent of measured perirectal fat invasion into 3 mm or less and more than 3 mm. Five-year overall and local recurrence rates for the entire group were 19% and 8%, respectively. The disease-free survival, disease-specific survival, and overall recurrence for rectal cancers with 3 mm or less invasion vs. more than 3 mm invasion, or T3 gross vs. T3 microscopic, were not statistically different. CONCLUSION: Our data suggest that the extent of gross, or microscopic perirectal fat invasion (defined as >3 or

Subject(s)
Adipose Tissue/pathology , Neoplasm Invasiveness , Rectal Neoplasms/pathology , Rectal Neoplasms/surgery , Surgical Procedures, Operative/methods , Adult , Aged , Aged, 80 and over , Databases, Factual , Disease-Free Survival , Humans , Male , Middle Aged , Prognosis , Prospective Studies , Radiotherapy, Adjuvant
SELECTION OF CITATIONS
SEARCH DETAIL
...